Perioperative management of ruxolitinib in primary myelofibrosis during coronary artery bypass graft surgery

Clicks: 1
ID: 322989
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #74 of 80 articles by views in Interdisciplinary CardioVascular and Thoracic Surgery

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm frequently treated with the Janus kinase (JAK) inhibitor Ruxolitinib. Perioperative management of Ruxolitinib presents a clinical dilemma. Continued therapy may increase the risk of infection, cytopenia, and impaired wound healing during major surgery, whereas abrupt discontinuation can precipitate Ruxolitinib Discontinuation Syndrome (RDS), an inflammatory rebound syndrome that may be life-threatening. Currently, there are no established perioperative guidelines for the management of Ruxolitinib. We report a case of a 65-year-old patient with PMF undergoing elective coronary artery bypass graft (CABG) surgery. Following multidisciplinary discussion with haematology, Ruxolitinib was withheld for 48 hours perioperatively and prophylactic corticosteroids were administered. The patient underwent uncomplicated surgery and recovery without evidence of infection, thrombocytopenia, or RDS. This case highlights the challenges associated with perioperative Ruxolitinib management and emphasises the importance of multidisciplinary decision-making and individualised risk assessment. Reporting such cases contributes to the limited literature guiding perioperative management of JAK inhibitor therapy in patients undergoing major surgery.
Reference Key
openalex_W7171874686 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Michael Kay, Martin Yates, Emma O’Donovan, Lauren Tully
Journal Interdisciplinary CardioVascular and Thoracic Surgery
Year 2026
DOI
10.1093/icvts/ivag211
URL
https://doi.org/10.1093/icvts/ivag211
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.